Clinical trials: Refractory Neoplasm
B-cell Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or…
- Trial name
- NCT06450067
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- Juventas Cell Therapy Ltd.
Peripheral T Cell Lymphoma
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
Despite the use of monoclonal antibodies, checkpoint inhibitors, and bispecific T cell adapters (BiTE) Immunotherapies such as chimeric antigen receptor (CAR) T cells have completely changed the treatment methods of various…
- Trial name
- NCT05979792
- Testing
- CAR-T Therapy
- Where
- 8 sites in China
- Volunteers
- 35 people
- Sponsor
- Zhao Weili
Nasopharyngeal Carcinoma
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The aim of this study is to investigate the safety and preliminary efficacy of EBV CAR-T cells in the treatment of relapsed/refractory NPC
- Trial name
- NCT05654077
- Testing
- CAR-T Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- NCT00067028
- Testing
- Clofarabine 40mg/m^2, Idarubicin 10mg/m^2, Ara-C 0.75 g/m^2
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer
V-0039 is a Phase 1/2 dose escalation trial of CG7870 in combination with Docetaxel in metastatic hormone-refractory patients who have not received chemotherapy. All patients will receive docetaxel.
- Trial name
- NCT00103428
- Testing
- CG7870
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Cell Genesys
Ovarian Cancer
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in…
- Trial name
- NCT03989336
- Testing
- Manganese Chloride, nab-paclitaxel, Platinum chemotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Chinese PLA General Hospital
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
This phase II MATCH treatment trial tests how well nivolumab and BMS-986016 (relatlimab) works in treating patients with cancer that has certain genetic changes called LAG-3 mutations with mismatch repair deficiency.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06400264
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Metastatic Solid Tumor
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
- Trial name
- NCT04977453
- Testing
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib
- Where
- 13 sites in United States, South Korea
- Volunteers
- 317 people
- Sponsor
- GI Innovation, Inc.
Non-Hodgkin's Lymphoma, Lymphoma, Large Cell
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
- Conditions
- Non-Hodgkin's Lymphoma, Lymphoma, Large Cell, Diffuse, Mantle Cell Lymphoma, Lymphoma, Follicular Lymphoma
- Trial name
- NCT01118845
- Testing
- SyB L-0501, Rituximab
- Where
- 25 sites in Japan, South Korea
- Volunteers
- 63 people
- Sponsor
- SymBio Pharmaceuticals
Multiple Myeloma
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose.
- Trial name
- iinnovate-3 (NCT05590377)
- Testing
- Modakafusp Alfa, Daratumumab
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Amyloid, AL Amyloidosis
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in…
- Conditions
- Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
- Trial name
- NCT04270175
- Testing
- Daratumumab SC, Pomalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Cisplatin in Castration Resistant Prostate Cancer
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.
- Trial name
- NCT03275857
- Testing
- Cisplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Rochester
Advanced Solid Tumors, Multiple Myeloma
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
For cancer cells to grow, they need to have nutrients supplied to them through blood vessels. The study drug, ACE-041, is designed to work by blocking the growth of those blood vessels and preventing cancer cells from growing.
- Trial name
- NCT00996957
- Testing
- ACE-041
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Advanced Solid Tumors
A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors
This study is designed to characterize the absorption, distribution, metabolism and excretion (ADME) of ASA404 following a single intravenous administration of 3000 mg (approximately 1800 mg/m2) ASA404 containing 60 µCi of 14C…
- Trial name
- NCT01299701
- Testing
- ASA404
- Where
- New Zealand
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
This study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).
- Trial name
- NCT07784101
- Testing
- ICP-248, Pirtobrutinib, Orelabrutinib
- Where
- 24 sites in China
- Volunteers
- 280 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
B-Cell Lymphoma
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
This study will examine the safety and effectiveness of an experimental drug called Bortezomib (PS-341), given alone and in combination with a chemotherapy regimen called Etoposide, Prednisone, Vincristine, Cyclophosphamide…
- Trial name
- NCT00054665
- Testing
- PS-341, Etoposide, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
This phase I trial studies the side effects and the best dose of alisertib when given together with vorinostat in treating patients with Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, or peripheral T-cell lymphoma that has come…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT01567709
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Tumors, Lymphoma
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT00060645
- Testing
- ridaforolimus
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer, Hormone Refractory Prostate Cancer
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
PURPOSE: The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory…
- Trial name
- NCT00069745
- Testing
- Satraplatin, Prednisone
- Where
- 211 sites in United States, Argentina and 13 more
- Sponsor
- Agennix
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.
- Trial name
- NCT07260812
- Testing
- KSV01 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- TCRx Therapeutics Co.Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.